Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy
Open Access
- 5 October 2022
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 176, 110-120
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (A24604)
- Imperial Experimental Cancer Medicine Centre
- Imperial College London
- Medical Research Council (MC-A652-5PY80)
- Imperial College Healthcare NHS Trust
- NIHR Imperial Biomedical Research Centre
- National Institute for Health and Care Research
This publication has 36 references indexed in Scilit:
- Concise Drug Review: Azacitidine and DecitabineThe Oncologist, 2013
- Dynamic DNA methylation across diverse human cell lines and tissuesGenome Research, 2013
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Chemical Decomposition of 5-Aza-2′-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass SpectrometryChemical Research in Toxicology, 2009
- Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumorWorld Journal of Gastroenterology, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Delivery of 5-Aza-2′-Deoxycytidine to Cells Using OligodeoxynucleotidesCancer Research, 2007
- Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or PleuraClinical Cancer Research, 2006
- Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derivedOncogene, 2002